Donya Pakravan

• • Managed approximately 20 concurrent innovation and BD projects across biologics, AI/ML drug discovery, diagnostics, and enabling technologies, reporting to the VP of Innovation in a GBP 500M+ R&D organisation.

• • Conducted scientific, commercial, and IP due diligence on 200+ companies and assets, generating structured investment recommendations and go/no-go analyses for senior leadership.

• • Built financial models (rNPV, DCF, TAM/SAM, scenario analyses) and competitive landscapes to support GBP 50M+ portfolio allocation decisions.

• • Originated and executed 10-15 strategic partnerships (co-development, in-licensing, revenue-sharing, OEM), independently leading all commercial negotiations end-to-end.

• • Managed external research vendors and partners, briefing on objectives, quality-assuring outputs, and integrating findings into board-level recommendations.

• • Delivered whitespace and competitive landscape analyses across biologics, proteomics, and diagnostics, producing board-level strategic recommendations on portfolio prioritisation and investment.

• • Built structured decision frameworks and scenario models for build/buy/partner choices across key therapeutic and technology areas.

• • Delivered strategy and commercial evaluation engagements for top-5 global pharma clients across oncology, diagnostics, rare disease, and neuroscience, leading teams of 3-4 analysts and consultants.

• • IVD and CDx subject matter expert on a global top-10 pharma precision medicine engagement; led competitive strategy and launch planning for liquid biopsy and ctDNA detection assets.

• • Conducted primary KOL research with oncologists, pathologists, and diagnostic specialists; synthesised conference intelligence from ASCO, ESMO, and AACR into C-suite strategic recommendations.